Highest-materiality recent filing
Elicio hosts KOL event on ELI-002 7P for metastatic mKRAS PDAC; no new data disclosed
Virtual KOL event on June 24, 2026 featured Dr. Zev Wainberg (UCLA) and Dr. Peter Hosein (U. Miami).
Elicio reports 3 complete responses post-ELI-002 7P with checkpoint inhibition in mPDAC
100% confirmed complete radiographic and metabolic responses in 3 patients who progressed on ELI-002 7P and received nivolumab-based therapy.
Elicio Phase 2 AMPLIFY-7P misses primary DFS endpoint; positive R0 subgroup guides Phase 3
AMPLIFY-7P did not meet primary endpoint of DFS in ITT; R1 resection imbalance (19% vs 10%) favored observation arm.
Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4
Q1 net loss $11.8M ($0.65/sh) vs $11.2M ($0.87/sh) YoY; R&D $6.8M, G&A $3.8M.
Elicio Therapeutics enters $100M ATM facility; terminates prior $40M JonesTrading ATM
Company entered ATM sales agreement to sell up to $100M of common stock through B. Riley Securities, JonesTrading, and Ladenburg Thalmann.
Net loss for 2025 was $39.5M ($2.58 per share), compared to $51.9M ($4.25) in 2024.
Elicio Q3 net loss $10.1M ($0.60/sh); Phase 2 DFS analysis pushed to 1H 2026 on fewer events
Phase 2 AMPLIFY-7P: fewer disease progressions/deaths than projected; event-driven primary DFS analysis now expected 1H 2026.
Elicio reports 99% T cell response rate in Phase 2 AMPLIFY-7P trial of ELI-002 7P
ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90).
Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction
At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.
Elicio Q2 net loss $10.6M; IDMC positive for ELI-002 Phase 2; DFS readout Q4 2025
IDMC recommended continue ELI-002 Phase 2 pancreatic study without modification; final DFS analysis expected Q4 2025.
IDMC recommended AMPLIFY-7P trial continue to final analysis without modifications based on pre-specified interim review of safety and efficacy.
Elicio Therapeutics secures $10M senior secured note from board-affiliated investor
Issued $10M promissory note to GKCC (controlled by board member); interest rate up to 12.5%.
Elicio Therapeutics stockholders elect two directors, ratify auditor at annual meeting
Karen J. Wilson elected with 8,588,077 votes for, 420,412 against; 2,154,961 broker non-votes.
Elicio reports Q1 net loss of $11.2M; cash into Q4 2025; Phase 2 interim analysis Q3 2025
Net loss of $11.2M ($0.87 per share) for Q1 2025 vs $11.8M ($1.15) in Q1 2024.
Elicio Therapeutics reports year-end 2024 results; press release text unreadable
Filing announces financial results for year ended Dec 31, 2024 and corporate updates.
Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer
Preetam Shah appointed Chief Strategy and Financial Officer effective March 24, 2025; will become Principal Financial Officer and Principal Accounting Officer on April 1, 2025.
Elicio Therapeutics (ELTX) settles $20M convertible note, issues 3.5M shares
Converted $20M 3.0% Senior Secured Convertible Note due Feb 2026 into 3,500,573 common shares on March 5, 2025.
Elicio Therapeutics raises $10M in registered direct offering of shares and warrants
Gross proceeds of $10.0M from sale of 1,261,830 shares and warrants priced at $7.925 per unit.
Elicio posts corporate deck; no extractable clinical/financial data in filing text
Corporate presentation posted on company website dated January 23, 2025.
Elicio receives supportive FDA feedback on ELI-002 Phase 3 registrational strategy
FDA aligned on Phase 3 study design: dose, schedule, patient population (KRAS-mutated pancreatic cancer), and DFS endpoint.
Elicio Therapeutics Reports Updated Phase 1 Data for ELI-002 at ESMO Immuno-Oncology Congress 2024
Updated Phase 1 data show 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population (n=25).
Elicio Therapeutics completes enrollment of 135 patients in Phase 2 AMPLIFY-7P study for ELI-002
Phase 2 study ELI-002 7P enrolled 135 mKRAS-driven PDAC patients post-surgery, randomized 2:1 vs observation.
Elicio Therapeutics shareholders elect directors, ratify auditor, approve share issuance
Three Class I directors elected: Robert Connelly (6,248,397 for), Katie Chudnovsky (6,233,264), Allen Nissenson (6,249,739).
Elicio Therapeutics Q3 2024 net loss $18.8M, cash $26M; AMPLIFY-7P enrollment on track
Net loss $18.8M ($1.39 per share) vs $10.7M ($1.27) YoY; includes $8.5M non-cash warrant liability change.
Elicio Therapeutics annual meeting adjourned due to lack of quorum; reconvened Nov 21
Virtual annual meeting on Nov 7, 2024 lacked a quorum of common stock holders.
All 12 evaluable patients showed mKRAS-specific T cell responses; RP2D group had 12-fold higher median response vs 1.4 mg group.
Elicio Therapeutics appoints CEO Robert Connelly as Principal Financial and Accounting Officer
Robert Connelly, already CEO and President, appointed as Principal Accounting Officer and Principal Financial Officer effective Oct 15, 2024.
Elicio Therapeutics CFO Brian Piekos resigns effective September 6, 2024
CFO Brian Piekos notified Company of resignation on Aug 27, 2024, to pursue other opportunity.
Elicio Q2 net loss $7.2M; Phase 1 data show 100% T cell response; Phase 2 enrollment Q4
Net loss of $7.2M ($0.64 per share) for Q2 2024; cash $3.4M at June 30, but subsequent financings raised ~$29.6M net.
Elicio Therapeutics closes $20M convertible note private placement at $5.81 conversion price
Raised $20M via 3% senior secured convertible note due Feb 2026; net proceeds ~$19.7M.
Elicio Therapeutics prices $11.5M public offering of common stock and warrants
Gross proceeds ~$11.5M; net proceeds ~$10.9M after discounts and expenses.
Median DFS not reached in 14 patients; median follow-up 29.1 weeks.
Elicio reports preliminary Phase 1a data for ELI-002 7P: 100% T cell response, biomarker reductions
ELI-002 7P generated mKRAS-specific T cell response in 100% (11/11) evaluable patients; responses against all mutations enrolled.
Elicio Therapeutics reports Q1 2024 net loss of $11.8M; provides clinical updates for ELI-002
Net loss $11.8M ($1.15 per share) vs $8.0M in Q1 2023; R&D expense increased to $7.6M from $5.5M.
Elicio reports 84% CD8+ T cell response and antigen spreading in ELI-002 Phase 1 at AACR
68% of patients developed cytotoxic mKRAS-specific CD4+ T cells; 84% developed CD8+ T cells.
Elicio Therapeutics reports FY2023 net loss $35.2M; cash boosted by $6M private placement
Net loss of $35.2M for FY2023 vs $28.2M in FY2022; diluted EPS -$6.96 vs -$89.27 (reverse-merger impact).
Elicio raises $6.0M via pre-funded warrants sale to board-member entity GKCC, LLC
Private placement of pre-funded warrants for 1,032,702 shares at $5.81 each; gross proceeds ~$6.0M.
Elicio raises CEO/CSO base pay, grants 225k/30k stock options, adopts severance plan
CEO base salary raised to $608,400; annual performance bonus opportunity set at 55% of base.
Elicio presents ELI-002 7P Phase 1/2 trial design at ASCO GI; Phase 1A complete, Phase 2 enrolling
Phase 1A completed with no dose-limiting toxicities; Phase 2 randomized 2:1 study enrolling PDAC patients.
Elicio raises ~$4.9M from ATM equity sales since Q3 2023
Issued and sold 584,170 shares under at-the-market program since September 30, 2023.
Elicio reports Phase 1 data for ELI-002: 84% T cell response, 16.3-month median RFS
AMPLIFY-201 data published in Nature Medicine in 25 patients (20 pancreatic, 5 colorectal) with minimal residual mKRAS disease.
Elicio Therapeutics raises $7M via private placement at $5.81/share to board-affiliated entity
Private placement of 1,213,000 shares at $5.81 per share to GKCC, LLC, controlled by a board member.
Elicio Therapeutics Q3 net loss $10.7M; ELI-002 RFS 16.3 months, Phase 2 planned early 2024
Net loss of $10.7M ($1.27/sh) vs $7.2M loss ($22.67/sh) in Q3 2022; cash $14.1M vs $6.2M year-end 2022.
ELI-002 Phase 1: 87% (20/23) of patients had direct ex vivo mKRAS-specific T cell responses; 100% in vitro.
Annette Matthies, Ph.D. ceased as Chief Business Officer; separation agreement signed October 19, 2023.
Elicio Therapeutics terminates Chief Business Officer Annette Matthies without cause
Annette Matthies, Ph.D., Chief Business Officer, terminated without cause effective October 5, 2023.
Elicio reports ELI-002 Phase 1 data: median RFS not reached vs 3.9 months, HR=0.14
Median RFS not reached for high T cell responders vs 3.9 months for low (HR=0.14; p=0.013).
Elicio Therapeutics receives $2.6M grant from GI Research Foundation for two cancer vaccines
Grant awarded on Sept 7, 2023, adds to $2.8M received in Sept 2022 from GIRF.
Elicio Therapeutics director Assaf Segal resigns effective August 28, 2023
Assaf Segal resigned from the Board of Elicio Therapeutics, effective immediately on August 28, 2023.
Private Elicio net loss of $8.0M for Q1 2023; accumulated deficit $115.0M at March 31, 2023.
On March 21, 2025, Elicio Therapeutics, Inc. (the “Company”) appointed Preetam Shah, Ph.D., M.B.A., as the Company’s Chief Strategy and Financial Officer effective as of March 24, 2025 (the “Effective Date”).
On October 15, 2024 , Elicio Therapeutics, Inc. (the “Company”) appointed Robert Connelly as the Company’s Principal Accounting Officer and Principal Financial Officer effective October 15, 2024.
On August 27, 2024, Brian Piekos, the Chief Financial Officer and Treasurer of Elicio Therapeutics, Inc. (the “Company”), informed the Company of his intent to resign from his positions, effective September 6, 2024, to pursue another opportunity.
On October 19, 2023 , Elicio Therapeutics, Inc. (the “Company”) and Annette Matthies, Ph.D., former Chief Business Officer of the Company, entered into a Separation and Release Agreement
On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the “Company”) was terminated without cause, effective as of the same date (the “Separation Date”).
On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors (the “Board”) of Elicio Therapeutics, Inc. (the “Company”), which resignation was effective immediately.
Annette Matthies, Ph.D. 46 Chief Business Officer
Yekaterina (Katie) Chudnovsky 38 Class I Director
Brian Piekos 48 Chief Financial Officer
(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.
(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.
Christopher Haqq, M.D., Ph.D. 57 Executive Vice President, Head of Research and Development and Chief Medical Officer
Max materiality 0.85 · Median 0.65 · Most common event other_material